Akorn acquires Betimol from Santen, to add $0.03-$0.04 in EPS in 2014

|By:, SA News Editor

Akorn (AKRX -0.3%) acquires the NDA and all rights to Betimol 0.25% and 0.5%, a prescription eye drop medicine for ocular hypertension/glaucoma, from Santen. It plans to begin shipment in Q1.

Betimol is expected to add $0.03-$0.04 in EPS on $8M-$9M in revenue in 2014.

Previous: Akorn acquires eye drop solutions from Merck in $52.8M deal